Top

Published in:

01-03-2018 | Review Article

Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study

Authors: Francesco Caso, Antonio Del Puente, Francesca Oliviero, Rosario Peluso, Nicolò Girolimetto, Paolo Bottiglieri, Francesca Foglia, Carolina Benigno, Marco Tasso, Leonardo Punzi, Raffaele Scarpa, Luisa Costa

Published in: Clinical Rheumatology | Issue 3/2018

Abstract

The aim of this study was to evaluate the prevalence of MetS and its components and the level of serum uric acid in patients with PsA and in those with PsA sine psoriasis. A secondary aim of the study was to investigate on correlations of MetS in all study population. Consecutive PsA patients underwent assessment of disease activity and metabolic parameters. Blood samples were collected after 12 h of overnight fasting and analyzed for glucose, lipid profile, serum uric acid, and acute-phase reactants. The NCEP-ACT III criteria were used to identify subjects with MetS. Forty-two patients (52.5%) were classified as having PsA with clinically evident psoriasis (group 1) and 38 (47.5%) as having PsA sine psoriasis (group 2). Group 1, when compared to group 2, showed a significant increase for the frequency of MetS (p = 0.006) and for mean values of diastolic blood pressure (p = 0.0116) and of serum uric acid (p = 0.04). We then aimed at defining determinants of MetS in the entire study population. In the multivariate analysis, three variables reached statistical significance: presence of psoriasis (OR 0.14; p = 0.01), increase of one unit of BMI (OR 1.26; p = 0.001), and smoking habit (OR 5.93; p = 0.02). In our study, the occurrence of MetS and mean levels of serum uric acid were higher in PsA patients with clinical evident psoriasis compared to sine psoriasis PsA. The results also show the potential role of BMI, psoriasis, and smoking as important determinants in the development of MetS in PsA patients.

Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78. https://doi.org/10.1016/0049-0172(73)90035-8 CrossRefPubMed

Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. Spring 3(1):759. https://doi.org/10.1186/2193-1801-3-759 CrossRef

Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L (2016) Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol 35(8):1893–1901. https://doi.org/10.1007/s10067-016-3295-9 CrossRefPubMed

Lapadula G, Marchesoni A, Salaffi F, Ramonda R, Salvarani C, Punzi L, Costa L, Caso F, Simone D, Baiocchi G, Scioscia C, Di Carlo M, Scarpa R, Ferraccioli G (2016) Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA). Reumatismo 68(3):126–136. https://doi.org/10.4081/reumatismo.2016.913 CrossRefPubMed

Nordmann A, Weber M (1999) Psoriatic arthritis without psoriasis. Schweiz Rundsch Med Prax 4:242–245

Olivieri I, Padula A, D'Angelo S, Cutro MS (2009) Psoriatic arthritis sine psoriasis. J Rheumatol Suppl 83(0):28–29. https://doi.org/10.3899/jrheum.090218 CrossRefPubMed

Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M, Ayala F, D'Arienzo A, Oriente P (2003) Clinical and genetic aspects of psoriatic arthritis “sine psoriasis”. J Rheumatol 30(12):2638–2640PubMed

Taylor W, Gladman D, Helliwell P, CASPAR Study Group et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed

Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39(1):154–156. https://doi.org/10.3899/jrheum.110845 CrossRefPubMed

10.

Chandran V, Schentag CT, Gladman DD (2007) Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 57(8):1560–1563. https://doi.org/10.1002/art.23104 CrossRefPubMed

11.

Scarpa R, Caso F, Costa L, Peluso R, Del Puente A, Olivieri I (2017) Psoriatic disease 10 years later. J Rheumatol 44(9):1298–1301. https://doi.org/10.3899/jrheum.161402 CrossRefPubMed

12.

Scarpa R, Caso F, Costa L, Peluso R, Spanò A, Lubrano E, Del Puente A, Moll JM (2015) Psoriatic disease: clinical staging. J Rheumatol Suppl 93(0):24–26. https://doi.org/10.3899/jrheum.150629 CrossRefPubMed

13.

Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365(9468):1415–1428. https://doi.org/10.1016/S0140-6736(05)66378-7 CrossRefPubMed

14.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef

15.

Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444(7121):860–867. https://doi.org/10.1038/nature05485 CrossRefPubMed

16.

Hutcheson J (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75(2):272–279. https://doi.org/10.1016/j.cyto.2015.04.004 CrossRefPubMed

17.

Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59(11):904–909. https://doi.org/10.1136/ard.59.11.904 CrossRefPubMedPubMedCentral

18.

Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology 47(5):718–723. https://doi.org/10.1093/rheumatology/ken090 CrossRefPubMed

19.

Özkan SG, Yazısız H, Behlül A, Gökbelen YA, Borlu F, Yazısız V (2017) Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with psoriatic arthritis. Eur J Rheumatol 4:40–45CrossRefPubMedPubMedCentral

20.

Goldman M (1981) Uric acid in the etiology of psoriasis. Am J Dermatopathol 3(4):397–404. https://doi.org/10.1097/00000372-198100340-00014 CrossRefPubMed

21.

Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359(17):1811–1821. https://doi.org/10.1056/NEJMra0800885 CrossRefPubMedPubMedCentral

22.

Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, Punzi L, Borghi C (2014) Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci 18(9):1295–1306PubMed

23.

Tsuruta N, Imafuku S, Narisawa Y (2017) Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol 44(12):1349–1352. https://doi.org/10.1111/1346-8138.13968 CrossRefPubMed

24.

Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8(4):331–334. https://doi.org/10.1089/met.2009.0124 CrossRefPubMedPubMedCentral

25.

Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63(2):195–202. https://doi.org/10.1002/acr.20363 CrossRef

26.

Labitigan M, Bahče-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, Putterman C, Broder A (2014) Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(4):600–607. https://doi.org/10.1002/acr.22185 CrossRef

27.

Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43(2):463–464. https://doi.org/10.3899/jrheum.150757 CrossRefPubMed

28.

Haque N, Lories RJ, de Vlam K (2016) Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol 43(2):376–382. https://doi.org/10.3899/jrheum.141359 CrossRefPubMed

29.

Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72(12):1956–1961. https://doi.org/10.1136/annrheumdis-2012-202325 CrossRefPubMed

30.

Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM (2012) Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 51(12):2215–2223. https://doi.org/10.1093/rheumatology/kes213 CrossRef

31.

Milaniuk S, Pietrzak A, Mosiewicz B, Mosiewicz J, Reich K (2015) Influence of psoriasis on circulatory system function assessed in echocardiography. Arch Dermatol Res 307(10):855–861. https://doi.org/10.1007/s00403-015-1586-7 CrossRefPubMedPubMedCentral

32.

Kassi E, Pervanidou P, Kaltsas G, Chrousos G (2011) Metabolic syndrome: definitions and controversies. BMC Med 9(1):48. https://doi.org/10.1186/1741-7015-9-48 CrossRefPubMedPubMedCentral

33.

Frati AC, Iniestra F, Ariza CR (1996) Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors. Diabetes Care 19(2):112–118. https://doi.org/10.2337/diacare.19.2.112 CrossRefPubMed

34.

Masulli M, Riccardi G, Galasso R, Vaccaro O (2006) Relationship between smoking habits and the features of the metabolic syndrome in a nondiabetic population. Nutr Metab Cardiovasc Dis 16(5):364–370. https://doi.org/10.1016/j.numecd.2005.06.005 CrossRefPubMed

35.

Owczarczyk-Saczonek AB, Nowicki R (2015) The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatol Alergol 32(5):331–336. https://doi.org/10.5114/pdia.2015.54743 CrossRefPubMedPubMedCentral

36.

Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157(1):68–73. https://doi.org/10.1111/j.1365-2133.2007.07986.x CrossRefPubMed

37.

Haroon M, Gallagher P, Heffernan E, FitzGerald O (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41(7):1357–1365. https://doi.org/10.3899/jrheum.140021 CrossRefPubMed

38.

Musacchio E, Perissinotto E, Sartori L, Veronese N, Punzi L, Zambon S, Manzato E, Baggio G, Corti MC, Crepaldi G, Ramonda R (2017) Hyperuricemia, cardiovascular profile, and comorbidity in older men and women: the Pro.V.A. Study. Rejuvenation Res 20(1):42–49. https://doi.org/10.1089/rej.2016.1834 CrossRefPubMed

39.

Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67(5):1739–1742. https://doi.org/10.1111/j.1523-1755.2005.00273.x CrossRefPubMed

40.

Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U (2003) Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 133(25-26):360–363PubMed

41.

Sautin YY, Nakagawa T, Zharikov S, Johnson RJ (2007) Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293(2):C584–C596. https://doi.org/10.1152/ajpcell.00600.2006 CrossRefPubMed

42.

Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114(12):1752–1761. https://doi.org/10.1172/JCI21625 CrossRefPubMedPubMedCentral

43.

Mahmood F, Coates LC, Helliwell PS (2017) Current concepts and unmet needs in psoriatic arthritis. Clin Rheumatol. https://doi.org/10.1007/s10067-017-3908-y

44.

Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31(4):711–715. https://doi.org/10.1007/s10067-011-1892-1 CrossRefPubMed

45.

Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33(6):833–839. https://doi.org/10.1007/s10067-013-2369-1 PubMed

46.

Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61(1-2):147–153. https://doi.org/10.1007/s12026-014-8595-z CrossRefPubMed

47.

Chimenti MS, Triggianese P, Conigliaro P, Tonelli M, Gigliucci G, Novelli L, Teoli M, Perricone R (2017) A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36(10):2253–2260. https://doi.org/10.1007/s10067-017-3769-4 CrossRefPubMed

Title: Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study
Authors: Francesco Caso
Antonio Del Puente
Francesca Oliviero
Rosario Peluso
Nicolò Girolimetto
Paolo Bottiglieri
Francesca Foglia
Carolina Benigno
Marco Tasso
Leonardo Punzi
Raffaele Scarpa
Luisa Costa
Publication date: 01-03-2018
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 3/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3975-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study

Changes and clinical significance of CD8+CD122+ T cells in the peripheral blood of patients with ankylosing spondylitis

Sodium valproate modulates immune response by alternative activation of monocyte-derived macrophages in systemic lupus erythematosus

Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study

Influence of air pollution on airway inflammation and disease activity in childhood-systemic lupus erythematosus

Translation and validation of the Chinese Social Role Participation Questionnaire in patients with ankylosing spondylitis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage